Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

SCOPE Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics

Coordinator
Scope Biosciences B.v., Netherlands
Runs
1 March 2024 to 28 February 2026
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101158803

What the project is doing

In the project's own words, from its summary on CORDIS.

In the healthcare sector, rapid and precise point-of-care diagnostics is indispensable for enhancing patient outcomes, particularly in critical scenarios such as sepsis and organ transplantations. Present In Vitro Diagnostic technologies often strike a compromise between accuracy, speed, portability, and cost-effectiveness. Immunoassays offer rapidity but sacrifice accuracy, while molecular diagnostics like PCR deliver accuracy at the expense of time and ease of use.

Isothermal molecular tests, on the other hand, are swift but lack specificity. Hence, a pressing need persists for point-of-care diagnostic tools that embody user-friendliness, cost-efficiency, high accuracy, and adaptability to diverse applications. At Scope Biosciences, a spin-off from Wageningen University, we have developed and patented a CRISPR-Cas diagnostic technology (scopeDx) that harnesses the precision of PCR and the speed of isothermal amplification, delivering rapid results within approximately 30 minutes at the point of care.

Futhermore, the scopeDx platform can be rapidly adapted to new applications. Our objective is to complete the pre-clinical validation of our solution to offer user-friendliness, robustness, portability, and cost-effectiveness, providing swift results directly at the point-of-care. Besides, we aim to prove the versatility of our platform, which can be extended to the detection of various pathogenic microbes (viruses, bacteria, fungi) and genomic applications (stem-cell & tissue transplantations).

In essence, scopeDx constitutes a modular platform technology with the potential to revolutionize the point-of-care diagnostics market comprehensively.

Topics

Who is involved

OrganisationCityCountryRole
Scope Biosciences B.v.WageningenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI